Avanos Medical, Inc. has recently acquired Nexus Medical, LLC, a company specializing in medical devices, in a move to strengthen its nutrition and medication delivery capabilities in critical care settings. Nexus is known for its proprietary tko® anti-reflux needleless connector technology, designed to support safer and more consistent nutrition and medication delivery in high-acuity settings, particularly in neonatal and pediatric intensive care units (NICUs and PICUs).
The acquisition of Nexus is significant in reinforcing Avanos' focus on providing safe and reliable therapy delivery for the neonatal patient population. Avanos expects immediate value from the acquisition, with the tko® needleless connector technology being a practical and trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease in NICU and PICU care.
The acquisition was financed with available cash, and Avanos anticipates it to be immediately accretive to both revenue growth and earnings per share. This move aligns with Avanos' strategy to deliver smarter, safer solutions across the critical care spectrum and invest in meaningful innovation to improve patient outcomes.
Avanos Medical, headquartered in Alpharetta, Georgia, is known for developing, manufacturing, and globally marketing its recognized brands, with leading market positions in multiple product categories. The company is committed to addressing critical healthcare needs, including providing vital nutrition support to patients and reducing the use of opioids while aiding patients in their transition from surgery to recovery. Today the company's shares have moved -1.53% to a price of $12.22. For more information, read the company's full 8-K submission here.
